FIELD: biochemistry.
SUBSTANCE: this invention relates to biochemistry, in particular to new polypeptides binding a human CD3 antigen and to molecules of bispecific antibodies capable of activating immune effector cells, as well as to their production and use in diagnostics or treatment of different diseases.
EFFECT: invention is aimed at reduction in a toxic effect of therapy using anti-CD3 antibodies with preservation of antitumor efficiency due to reduction in release of cytokines and reduction in off-target activation of T-cells.
58 cl, 10 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES BINDING CD3 | 2017 |
|
RU2779489C2 |
| ANTIBODIES BINDING TO GPRC5D | 2019 |
|
RU2797268C2 |
| ANTIBODY TO CD3 AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2802272C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2022 |
|
RU2824285C2 |
| COMBINATION THERAPY BASED ON T-CELL-ACTIVATING BISPECIFIC ANTIGEN-BINDING MOLECULES AGAINST CD3 AND FOLATE RECEPTOR 1 (FOLR1) AND ANTAGONISTS BINDING TO PD-1 AXIS | 2015 |
|
RU2753902C2 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| ANTIBODIES BINDING TO CD3 | 2019 |
|
RU2810924C2 |
| CD3 BINDING ANTIBODIES | 2017 |
|
RU2807216C2 |
| BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3 | 2018 |
|
RU2778805C2 |
| HER-2-DIRECTED ANTIGEN-BINDING MOLECULES CONTAINING 4-1BBL | 2019 |
|
RU2815451C2 |
